BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2019/2/261 分で読めます

Assessing the Effects of Food on Drugs in Investigational New Drug Applications and New Drug Applications-Clinical Pharmacology Considerations; Draft Guidance for Industry; Availability

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Assessing the Effects of Food on Drugs in INDs and NDAs--Clinical Pharmacology Considerations." This draft guidance provides recommendations to sponsors planning to conduct food-effect trials for orally administered products as part of investigational new drug applications (INDs), new drug applications (NDAs), and supplements to these applications. This draft guidance, when final, revises and replaces part of the 2002 FDA guidance for industry entitled "Food-Effect Bioavailability and Fed Bioequivalence Studies" (2002 Food Effect Guidance).

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

関連インサイト

ビジネスインサイト →